Missed 2nd Initiation Dose: 4-7 Weeks Since 1st injection

Tutorial Print Graph Information
Dose Information

Graph Information

^ Back to Top

INVEGA SUSTENNA® 2nd Initiation Dose: 4-7 weeks since 1st injection

Consistent with the INVEGA SUSTENNA® Prescribing Information:

  • If the target date for the second INVEGA SUSTENNA® injection (one week ± 4 days) is missed, the recommended reinitiation depends on the length of time which has elapsed since the patient's first injection.
    • TIMING OF MISSED SECOND INITIATION DOSE DOSING
    4 to 7 weeks since first injection Resume dosing with two injections of 156 mg in the following manner:
    1. Administer a deltoid injection as soon as possible.
    2. Administer a second deltoid injection 1 week later.
    3. Thereafter, resume regular monthly dosing in either the deltoid or gluteal muscle.
  • Administration: Each injection must be administered only by a healthcare professional. INVEGA SUSTENNA® is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel.

INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

© Janssen Scientific Affairs, LLC 2024. All rights reserved. cp-45525v5

This site is published by Janssen Scientific Affairs, LLC, which is solely responsible for its contents.

This information is intended for healthcare providers in the United States only.

Last updated 8/24/2023

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel